Document is current
Any future updates will be listed below
-
Authors
Amoaku, Winfried M. https://orcid.org/0000-0001-5028-7984
Cushley, Laura
Silvestri, Vittorio
Akafo, Stephen
Amissah-Arthur, Kwesi N.
Lartey, Seth
Hageman, Courtney N.
Pappas, Christian M.
Hubbard, William C.
Bernstein, Paul S. https://orcid.org/0000-0002-4228-7666
Vitale, Albert
Roberts, Megan
Virgili, Gianni
Hageman, Gregory S.
Silvestri, Giuliana
,
Ahiabor, Edem K.
Atkins, Amos
Feilmeier, Jessica
Feilmeier, Michael
Hancox, Lisa S.
McCormick, Sheri L.
Miller, Norma
Nichols, Lisa R.
Cushley, Laura N.
Ferrin, Cóilin P.
Matthews, Stacie
Choi, Susie
Ricks, Christopher
-
Funding
Funding for this research was provided by:
University of Nottingham
U.S. Department of Health & Human Services | National Institutes of Health (RO1 EY014800)
Research to Prevent Blindness
- License Information
-
More Information
Article History
Received: 24 March 2023
Revised: 5 September 2023
Accepted: 7 September 2023
First Online: 29 September 2023
Competing interests
: WMA: Consultant for Abbvie, Alimera, Allergan Inc, Bayer, Bioeq, Novartis, Pfizer, Roche, Siloton and Thrombogenics, and has undertaken research sponsored by Allergan, Novartis, and Pfizer. He has received speaker fees and travel grants from Abbvie, Allergan, Bausch and Lomb, Bayer, Novartis, Pfizer, and Roche. WMA is a member of the <i>Eye</i> editorial board. PSB: Consultant for Alcon, Genentech, Kalsec, Kemin Health, Science Based Health, and has received Speaker fees from DSM, Kemin, and Sequenom and travel sponsorship from Koyo Mercantile. GSH: Scientific co-founder, CSO and shareholder for Perceive Biotherapeutics Inc.; Inventor/Co-inventor of patents owned by the University of Iowa and the University of Utah. GS: Consultant for Allergan, Bayer and Roche. AV: Consultant for Bausch and Lomb and ACIONT. SA, KNAA, LC, CNH, WH, SL, MR, CP, VS and GV: None.
